Close
Nordic 9Nordic 9

Théa Open Innovation (investor - Corporate Investor)

France theaopeninnovation.com
See something wrong or missing? Let us know
Offices:Paris

Théa Open Innovation is a sister company of Laboratoires Théa aiming to identify, evaluate and support the most innovative developments in eye care, by implementing license agreements and/or capital investments with partners

Average round investment:39.15M USD
Average number per year:1.0
Distribution: 2021 (1)
Portfolio companies: France Coave Therapeutics
Mostly invests in: France France (1) Biotech (1)

1 tracked investments in:

You need an account to access this feature. Log in or create one from here.

Do you have a question? Talk to us.

Investors with similar profile to Théa Open Innovation

Name Criteria
France Biocodex
73%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Common investees countries: France
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
France Lauxera Capital Partners
73%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Common investees countries: France
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
France Malakoff Humanis
73%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Common investees countries: France
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
France Didier Rousseau
73%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Common investees countries: France
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Belgium Bioqube Ventures
73%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Common investees countries: France
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Italy Principia SGR
73%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Common investees countries: France
  • Average number of deals per year: 2.0
  • Active last 12 months: Yes
United States SymBiosis
73%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Common investees countries: France
  • Average number of deals per year: 2.0
  • Active last 12 months: Yes
Netherlands Merck Ventures
73%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Common investees countries: France
  • Average number of deals per year: 2.2
  • Active last 12 months: Yes
Belgium V-Bio Ventures
72%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Common investees countries: France
  • Average number of deals per year: 1.2
  • Active last 12 months: Yes
Belgium SFPI-FPIM
72%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Common investees countries: France
  • Average number of deals per year: 1.5
  • Active last 12 months: Yes
Top